stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Return on equity
AbCellera Biologics Inc.'s return on equity over the twelve months to 30 June 2026 was −17.3%, down 2.8 percentage points from fiscal 2025 (−14.5%). Over the past ten years it has ranged from −65.9% (fiscal 2019) to 20.4% (fiscal 2020); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −14.5% | 0.28 |
| FY2024 | −14.8% | (2.48) |
| FY2023 | −12.3% | (26.30) |
| FY2022 | 14.0% | (2.50) |
| FY2021 | 16.5% | (3.90) |
| FY2020 | 20.4% | 86.37 |
| FY2019 | −65.9% | (74.28) |
| FY2018 | 8.34% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| ARQT Arcutis Biotherapeutics, Inc. compare | 14.9% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. compare | −38.0% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement